November 26, 2019 07:00 AM ESTUpdated 07:20 AM
R&D

OPDP let­ter crit­i­cizes drug com­pa­ny for fail­ing to dis­close risk in­fo on­line

Zachary Brennan

Senior Editor

The FDA Of­fice of Pre­scrip­tion Drug Pro­mo­tion (OPDP) on Mon­day un­veiled a new un­ti­tled let­ter sent last week to Michi­gan-based Rock­well Med­ical

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times